Rheumatology News

Spine injections should not be given to adults with chronic back pain because they provide little or no pain relief vs. sham injections, according to new clinical practice guidelines.

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.

TNF inhibitors for the treatment of axial spondyloarthritis may decrease the risk for hip or spine fracture by as much as 29% compared with NSAIDs, according to data published in Arthritis & Rheumatology.

For patients with rheumatoid arthritis and inadequate response to JAK inhibitors, cycling to another JAK inhibitor is a more effective option than switching to a biological disease-modifying antirheumatic drug, according to data.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

A significant number of children with juvenile idiopathic arthritis treated prior to the treat-to-target era demonstrated persistently active disease up to 5 years later, according to data from an Italian pediatric hospital.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell therapy that may bypass lymphodepletion, paving the way for a phase 1 trial in lupus and other autoimmune diseases.

The FDA has approved two new biosimilars of denosumab to treat osteoporosis, increase bone mass, prevent skeletal-related events for people with multiple myeloma and other indications, Samsung Bioepis announced.